Diaceutics are pleased to announce that Nick Roberts has joined the company as Chief Financial Officer and director of the board and has begun responsibilities of CFO as of March 18, 2022, replacing Philip White who has stepped down from the board and as Chief Financial Officer.
Nick is responsible for administrative, financial and risk management operations. He works with the executive leadership team (EXCO) and directors to develop and implement organizational strategies. His role involves maintaining investor relations, compliance with UK, US and Republic of Ireland financial reporting, taxation, and corporate governance standards.
Commenting on his new role, Nick said, “I am very excited and honoured to join Diaceutics at this important time in the company’s growth journey. Diaceutics are pioneers of precision medicine diagnostics technology and through their consistent growth and capabilities they are enabling pharmaceutical companies to deliver better and faster patient treatment decisions. I look forward to meeting and working with all the incredible people at Diaceutics as we build towards the goal of improving the quality of patient’s lives."
Nick joins the company from Ergomed plc, where he most recently served as Head of Group Reporting. Nick is a Fellow Chartered Accountant and an experienced senior finance professional with a demonstrated history of managing finance functions within high-growth AIM listed entities. Nick holds a BSc in Accounting and Finance from the University of Southampton.
“I am delighted to welcome Nick to the Executive team at this exciting time in our company’s evolution. He brings to the table a successful career with high growth AIM listed companies most recently in the pharmaceutical and green energy sector. Nick has a proven record of accomplishment in managing growth companies with a strong platform focus, partnered with strong technical accounting ability. Along with other recent announcements Nick joins a strengthening EXCO and broader leadership team and I look forward to working alongside him in the coming period,” said Peter Keeling, CEO of Diaceutics.
